Clinical Trials
5 trialsNCT05364073 2026-03-13
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
ArriVent BioPharma, Inc.
Phase 1 Active not recruiting
NCT04858958 2025-11-19
FAVOUR
Allist Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT05466149 2025-11-19
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Allist Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT05607550 2025-06-22
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
ArriVent BioPharma, Inc.
Phase 3 Active not recruiting
NCT03787992 2025-04-11
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
Allist Pharmaceuticals, Inc.
Phase 3 Active not recruiting